This menu provides the list of EV mRNAs identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Maximum false positive rate (FPR): Maximum true positive rate (TPR):
  - FPR is the probability that an absent mRNA accidently have higher intensity than that mRNA.
  - TPR is the percentile of mRNA among the present mRNAs.
    Please see user manual in the contact us/help menu for detail.
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Since there are multiple primers in the microarray, the same mRNA can have several FPR and TPR values.

mRNA name UniProt accession FPR TPR Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
(FPR<0.05,TPR<0.5)
Ubiquitin-conjugating enzyme E2 R1 (EC 6.3.2.19) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1)P49427 0.0e+0 4.6e-1RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls.
BMC Cancer. 2012 Jan 17;12:22. doi: 10.1186/1471-2407-12-22.		COG507830 / 0 / 30
Ubiquitin-conjugating enzyme E2 R1 (EC 6.3.2.19) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1)P49427 0.0e+0 4.4e-1RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls.
BMC Cancer. 2012 Jan 17;12:22. doi: 10.1186/1471-2407-12-22.		COG507830 / 0 / 30
Ubiquitin-conjugating enzyme E2 R1 (EC 6.3.2.19) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1)P49427 0.0e+0 4.3e-1RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls.
BMC Cancer. 2012 Jan 17;12:22. doi: 10.1186/1471-2407-12-22.		COG507830 / 0 / 30
Ubiquitin-conjugating enzyme E2 R1 (EC 6.3.2.19) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1)P49427 0.0e+0 3.7e-1Identifying mRNA, microRNA and protein profiles of melanoma exosomes.
PLoS One. 2012;7(10):e46874. doi: 10.1371/journal.pone.0046874. Epub 2012 Oct 9.		COG507830 / 0 / 30
Ubiquitin-conjugating enzyme E2 R1 (EC 6.3.2.19) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1)P49427 0.0e+0 4.5e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		COG507830 / 0 / 30
Ubiquitin-conjugating enzyme E2 R1 (EC 6.3.2.19) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1)P49427 0.0e+0 3.9e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		COG507830 / 0 / 30
Ubiquitin-conjugating enzyme E2 R1 (EC 6.3.2.19) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1)P49427 0.0e+0 3.5e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		COG507830 / 0 / 30
[1]